Jinarc tolvaptan

Jinarc (tolvaptan) is a breakthrough pharmaceutical product specifically designed for the treatment of autosomal dominant polycystic kidney disease (ADPKD). Developed by the Japanese healthcare giant Otsuka Pharmaceutical Co., Ltd., it represents the culmination of over 25 years of specialized research into vasopressin V2-receptor antagonists. The drug functions by inhibiting the progression of fluid-filled cysts in the kidneys, which helps preserve renal function and slow down the underlying pathophysiology of the disease. This specific packaging, indicated by the Italian text, represents its distribution in the European market.

The brand and its primary active ingredient, tolvaptan, were originally invented and brought to market by Otsuka in Japan. Today, the product is manufactured primarily in Japan, though Otsuka maintains a global network of production and distribution facilities to supply the drug to over 40 countries under various brand names, including Jynarque in the United States and Samsca for other indications. The brand is ultimately owned by Otsuka Holdings Co., Ltd., a leading global health-tech conglomerate headquartered in Tokyo, Japan, which oversees a vast portfolio ranging from pharmaceutical research to consumer nutraceuticals.